Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and produces a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor-cell survival and proliferation. Using a mouse model of spontaneous GIST, we found that the immune system contributes substantially to the antitumor effects of imatinib. Imatinib therapy activated CD8 + T cells and induced regulatory T cell (T reg cell) apoptosis within the tumor by reducing tumor-cell expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (Ido). Concurrent immunotherapy augmented the efficacy of imatinib in mouse GIST. In freshly obtained human GIST specimens, the T cell profile correlated with imatinib sensitivity and IDO expression. Thus, T cells are crucial to the antitumor effects of imatinib in GIST, and concomitant immunotherapy may further improve outcomes in human cancers treated with targeted agents.
GIST originates in the gastrointestinal tract and is the most common gastrointestinal sarcoma 1 . Approximately 75-80% of GISTs contain an activating KIT mutation, whereas 5-10% instead have a plateletgrowth factor receptor α (PDGFRA) mutation 2, 3 . Imatinib mesylate is a small-molecule inhibitor of KIT, PDGFRA, ABL and BCR-ABL tyrosine kinases. Imatinib induces a clinical response in approximately 80% of patients with advanced GIST and improves median overall survival from 9 months to over 5 years 4, 5 . Imatinib therapy for GIST is one of the most successful applications of targeted molecular therapy and has prompted the development of new targeted agents for a variety of other cancers.
Despite its effectiveness, imatinib is almost never curative in GIST. Disease progression occurs at a median of 18 months, most often owing to the emergence of resistant clones with secondary KIT or PDGFRA mutations 1 . One potential strategy to increase the efficacy of imatinib is to combine it with immunotherapy. Currently, understanding of the immune response to GIST is limited. Immunohistochemistry in human GIST has demonstrated the presence of intratumoral CD8 + T cells, T reg cells and macrophages 6, 7 . In patients with GIST treated with imatinib, progression-free survival correlates with IFN-γ secretion by peripheralblood natural killer (NK) cells 8 . Imatinib has also been shown to induce dendritic cells to activate NK cells in mice with other tumors 9 , although NK cells have been shown to be largely absent in human GIST specimens 7 . Overall, then, the importance of the immune system in patients with GIST treated with imatinib remains largely undefined. Therefore, we studied the immune response to GIST during imatinib therapy to assess the potential of combining targeted and immune therapy.
RESULTS

CD8 + T cells contribute to antitumor effects of imatinib
To investigate the role of the immune response to imatinib in GIST, we used a transgenic GIST mouse (Kit V558/+ ) that spontaneously develops a single GIST in the cecum by 4 weeks of age owing to an activating mutation in the Kit gene 10 . The tumor is similar to human GIST in morphology, oncogenic Kit signaling and sensitivity to imatinib ( Supplementary Fig. 1) 10, 11 . Imatinib rapidly decreased tumor weight ( Fig. 1a and Supplementary Fig. 1) , which correlated with a specific loss of Kit + tumor cells ( Supplementary Fig. 1 ). By day 8, tumors had less uptake of 18 fluoro-deoxyglucose (FDG) according to positron emission tomography (PET) scans ( Fig. 1b) , as occurs in humans 1 . Imatinib increased the number and activation of CD8 + T cells in the mesenteric draining lymph nodes (DLNs) of GIST mice but not the inguinal nodes of GIST mice or DLNs of wild-type mice (Fig. 1c) . Imatinib increased the frequency of tumor-specific CD8 + T cells in the DLN (Fig. 1d) . Within the tumor, imatinib induced a marked increase in CD8 + T cell frequency, number ( Fig. 1e) and proliferation ( Fig. 1f) . Activation measured by CD69 expression and cytolytic capacity determined by granzyme B expression were also increased ( Fig. 1g) . Histology revealed that CD4 + (data not shown) and CD8 + T cells diffusely infiltrated the tumor at baseline (Fig. 1h) . After imatinib, there was no change in the production of interleukin-4 (IL-4), IL-17 or IFN-γ by CD4 + T cells ( Supplementary Fig. 2 Fig. 3) .
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To determine the role of CD8 + T cells during imatinib therapy, we depleted them with a monoclonal antibody. The antitumor effects of imatinib were less in mice depleted of CD8 + but not CD4 + T cells, NK cells ( Fig. 1i ) or myeloid cells ( Supplementary Fig. 4 ). GIST-Rag1 −/− mice, which lack mature T and B cells, had larger tumors than aged-matched controls, but GIST-µMT −/− mice, which lack B cells, did not ( Supplementary Fig. 4 ). Furthermore, imatinibnaive GIST mice depleted for 4 weeks of CD8 + but not CD4 + T cells, NK cells or B cells had larger tumors ( Supplementary Fig. 4 ). Together, these results indicate that imatinib amplifies a preexisting immune response in mouse GIST, and CD8 + T cells are required for its maximal effects.
Imatinib modulates intratumoral T cells through inhibition of Ido
We next analyzed whether imatinib altered T reg cells, as these cells have a vital role in the suppression of antitumor immune responses 12 . Notably, imatinib decreased the frequency and number of T reg cells in the tumor, but not in the DLN (Fig. 2a ) or spleen (data not shown). Consistent with this finding, T reg apoptosis occurred selectively within the tumor (Fig. 2b) . As a result, imatinib significantly increased the ratio of CD8 + T cells to T reg cells in the tumor, but not in the DLN (Fig. 2c ) or spleen (data not shown). The ratio of intratumoral effector T cells (T eff cells) to T reg cells is known to correlate with a favorable immunological outcome against tumors in both mice and humans [13] [14] [15] .
To investigate how imatinib affects intratumoral CD8 + T cells and T reg cells, we performed gene expression array analysis of mouse GIST tumors. Among the largest differences after imatinib treatment was lower expression of intratumoral Ido1 mRNA (encoding Ido) ( Supplementary Table 1 and Fig. 3a) . The expression of immunomodulatory cytokines IL-1β, IL-6, tumor necrosis factor-α, IL-17, IL-10 and interferon-γ (IFN-γ) were not altered by imatinib ( Supplementary Fig. 5 ). Ido protein catalyzes the conversion of tryptophan into immunosuppressive metabolites, which promote the development, stabilization and activation of T reg cells while also suppressing T eff cells [16] [17] [18] [19] [20] [21] . Western blotting confirmed that Ido protein was expressed at high levels at baseline in the tumor but not in the DLN or spleen, and expression was decreased substantially by imatinib ( Fig. 3a) . Ido protein was present in CD45 − Kit + tumor cells but not CD45 + intratumoral lymphocytes (Fig. 3a) . The overall reduction in tumor Ido protein by imatinib ( Fig. 3a) did not result merely from the loss of tumor cells, as Ido protein levels were also lower on a percell basis in live tumor cells treated with imatinib.
To determine whether the reduction of intratumoral Ido levels had functional consequences, we administered the specific Ido inhibitor 1-methyl-d-tryptophan (1-MT) to GIST mice. 1-MT alone decreased tumor weight, and, notably, CD8 + T cells were required for this effect (Fig. 3b) . Ido blockade alone increased the proliferation and activation of intratumoral CD8 + T cells ( Fig. 3c) , but not other immune cells (data not shown). Furthermore, the number and frequency of intratumoral T reg cells were reduced (data not shown) owing to T reg apoptosis within the tumor but not in the DLN (Fig. 3d) . Apoptosis occurred preferentially in T reg cells and was not observed in CD8 + T cells or other immune cells with Ido inhibition (data not shown). As a result, there was an increase in the ratio of intratumoral CD8 + T cells to T reg cells (Fig. 3e) . These observations from Ido inhibition were reminiscent of our findings in GIST mice treated with imatinib. Therefore, we hypothesized that the immune effects of imatinib are partially mediated by its reduction of Ido expression. To test this, we treated GIST mice with imatinib and a cocktail of immunosuppressive tryptophan metabolites (l-kynurenine, 3-hydroxyanthranilic acid and 3-hydroxykynurenine) to circumvent Ido inhibition during imatinib therapy. The administration of tryptophan metabolites diminished the antitumor effects of imatinib ( Fig. 3f ). Of note, concomitant administration of 1-MT did not increase the antitumor effects of imatinib, consistent with the hypothesis that their mechanisms may overlap (Fig. 3f ). Tryptophan metabolites effectively blocked imatinib-mediated upregulation of CD69 and granzyme B in intratumoral CD8 + T cells ( Fig. 3g ) and apoptosis of intratumoral T reg cells (Fig. 3h) , thereby preserving the baseline ratio of intratumoral CD8 + T cells to T reg cells (Fig. 3i) . Thus, our data suggest that imatinib induces intratumoral CD8 + T cell activation and regulatory T cell apoptosis in mouse GIST through the inhibition of Ido.
Imatinib downregulates IDO by inhibiting oncogenic KIT signaling
To establish how imatinib downregulates tumor-cell expression of Ido, we analyzed a human GIST cell line (GIST-T1) in which oncogenic KIT signaling is driven by a KIT exon 11 mutation 22 , similarly to our mouse model. We also performed additional studies using a subclone of GIST-T1 called GIST-T1R, which became resistant to imatinib after chronic, intermittent exposure to the drug during culture. GIST-T1R cells acquired a secondary mutation in KIT exon 13, V654A, as can occur in patients with GIST 23 . Imatinib potently inhibited IDO expression in live GIST-T1 cells on a per-cell basis, but not in GIST-T1R cells ( Fig. 4a) , suggesting that imatinib-mediated reduction of IDO levels depended on the ability of imatinib to block KIT signaling. Imatinib rapidly decreased Ido1 mRNA expression, resulting in lower Ido1 levels after in vivo treatment in bulk tumor and sorted tumor cells ( Fig. 4b) . IFN-α, IFN-β and IFN-γ are among the strongest inducers of IDO 24 . IFN-α and IFN-β signaling depend on the translational repressor 4-EBP1 and transcriptional activator S6, both of which are activated by mammalian target of rapamycin (mTOR) [25] [26] [27] [28] . mTOR is a downstream component of the oncogenic KIT-PI3K-AKT pathway that is constitutively active, central to GIST oncogenesis and inhibited by imatinib 11 . Rapamycin, an inhibitor of mTOR, was sufficient to reduce IDO expression in GIST-T1 cells (Fig. 4c) .
To identify other potential regulators of Ido1 transcription, we analyzed predicted binding sites within its promoter region. Etv4, a transcription factor and one of the genes whose expression was most reduced with imatinib treatment on our array ( Supplementary  Table 1 and Fig. 4d) , was identified as a highly likely candidate. Imatinib rapidly reduced Etv4 mRNA levels in vivo in bulk tumor and sorted tumor cells ( Fig. 4e) . In addition, imatinib treatment resulted in lower levels of IDO and ETV4 protein in mouse tumors and GIST-T1 cells, and also reduced phosphorylated KIT, STAT3 and S6 abundance (Fig. 4f) , as previously shown 11 . Consistent with Etv4 having the potential to regulate Ido1 transcription, Etv4 bound the Ido1 promoter, as shown by chromatin immunoprecipitation (ChIP) experiments, in vehicle-treated mice but not in imatinibtreated mice (Fig. 4g) .
T cell profile correlates with imatinib sensitivity in human GIST
To determine the clinical relevance of our findings in mouse GIST, we analyzed the immune infiltrate in 45 matched blood and tumor specimens that were freshly obtained from 36 individuals with GIST undergoing surgery (Supplementary Table 2 ). Tumors were classified as sensitive or resistant to imatinib (based on serial radiologic assessment) or as untreated.
Compared with resistant tumors, sensitive tumors contained greater frequencies of CD3 + and CD8 + T cells, but a lower percentage of CD4 + T cells (data not shown) and T reg cells (Fig. 5a) . Fig. 6 and data not shown). There were no differences in percentages of intratumoral NK cells as shown by tumor response (Supplementary Fig. 6 ). Irrespective of treatment status and tumor response, intratumoral CD8 + T cells were activated, as shown by greater CD69 and CD25 expression, compared with CD8 + T cells from the blood of the same patient (Fig. 5b) . Consistent with our findings in mouse GIST, the ratio of intratumoral CD8 + T cells to T reg cells was greater in imatinib-sensitive tumors compared with untreated tumors (Fig. 5c) . Notably, the intratumoral CD8 + T cell to T reg ratio was lower in resistant tumors compared with sensitive GISTs (Fig. 5c) . In two of three patients who had coexistent sensitive and resistant tumors removed simultaneously, we observed a higher ratio of CD8 + T cells to T reg cells in the sensitive tumors (Fig. 5d) . Moreover, in 13 patients whose freshly isolated tumors were tested immediately for IDO by flow cytometry, the ratio of intratumoral CD8 + T eff to T reg cells correlated with IDO protein expression ( Fig. 5e) . IDO1 mRNA distinguished sensitive and resistant tumors, with substantially greater IDO1 mRNA in resistant than in sensitive tumors ( Supplementary  Fig. 7) . Thus, the intratumoral T cell profile correlates to treatment response and IDO expression in human GIST. Imatinib and CTLA-4 blockade are synergistic in mouse GIST Although imatinib is highly effective, the drug eventually fails in the vast majority of patients with GIST. Given our finding that imatinib therapy depends on CD8 + T cells for its maximal effects, we investigated whether additional immune activation could augment its efficacy. We tested the combination of imatinib and blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a known modulator of effector T cells, T reg cells and Ido 29, 30 . Concurrent administration of imatinib and induction treatment with CTLA-4-specific blocking antibody for 1 week, followed by chronic CTLA-4 blockade, significantly decreased tumor size in established mouse GISTs compared with either treatment alone ( Fig. 6a and Supplementary Fig. 8 ). It has been shown that CTLA-4 blockade during priming can lead to accumulation of CD8 + T cells capable of producing effector cytokines such as IFN-γ 31 . GIST mice treated with imatinib and CTLA-4 blockade showed no change in the frequency or absolute number of CD4 + or CD8 + T cells in DLN or tumor (Fig. 6b,c) , or in the ratio of CD8 + T eff to T reg cells in the tumor (Fig. 6d) . Intratumoral CD8 + T cells showed a trend to enhanced IFN-γ production ( Fig. 6e) . Therefore, combined therapy of imatinib and CTLA-4 blockade has potential therapeutic promise for human GIST and may exert antitumor effects by increasing the frequency of IFN-γ-producing CD8 + T cells.
Immunohistochemistry confirmed the presence of CD8 + and CD4 + T cells and T reg cells infiltrating human GISTs (Supplementary
DISCUSSION
The discovery that oncogenic signaling pathways can be selectively inhibited using targeted agents has revolutionized the treatment of cancer 32 . Although imatinib has been thought to act primarily via direct effects on tumor cells, here we show that its action also relies considerably on indirect effects from the immune system. It is noteworthy that we found CD8 + T cell activation even though imatinib has been reported to block phosphorylation of CD8 + T cell leukocytespecific protein tyrosine kinase (LCK) in vitro 33 ; this blocking effect may, however, require supratherapeutic doses 34 . Our findings do not exclude the importance of other immune effectors during imatinib therapy, although depletion of CD4 + T cells or NK cells did not affect tumor weight, and the frequency of intratumoral NK cells did not correlate with treatment status in human GIST. Even though imatinib did not alter CD8 + T cells in the DLN or spleen of wild-type mice, both direct effects of imatinib on immune cells and indirect effects, such as through the release of tumor-cell contents, may be important in Ido1 transcription and T cell modulation. Further study will be necessary to identify the specific tumor antigens in mouse GIST. Human GISTs variably express cancer-testis antigens 35 . Nevertheless, identification of the immunoreactive epitopes for a particular GIST may be unnecessary, as imatinib may act as a vaccine through tumor destruction.
T reg cells are essential to tumor-induced peripheral tolerance and are a barrier to tumor immunotherapy 12 . Some cytotoxic agents deplete T reg cells systemically 36 . Previously, imatinib has been shown to reduce spleen T reg cells in BALB/c mice, albeit only in the absence of tumor 37 . We did not find that imatinib altered T reg cell frequency in the spleen or DLN of GIST mice or in the blood of humans with GIST. Therapeutic strategies to deplete T reg cells solely within the tumor are attractive, as they would avoid inducing autoimmunity from global T reg cell depletion. Recently, stimulation of glucocorticoid-induced tumor necrosis factor receptor (GITR) alone, or cyclophosphamide combined with OX40 stimulation, has been shown to deplete intratumoral T reg cells selectively in mouse melanoma, but the mechanism has not been identified 15, 38 . We found that imatinib selectively reduced intratumoral T reg cells by inhibiting Ido expression in GIST mice. Thus, whereas GIST cells show 'oncogene addiction' to KIT, intratumoral T reg cells in mouse GIST show 'Ido addiction' 39 . Our findings support the notion that tumors create mutually reliant immunosuppressive networks. Ido is crucial to T reg cells 17, [19] [20] [21] , and conversely, ligands expressed by T reg cells induce Ido 16, 40 . IDO appears to be instrumental in human cancers 41 , and we found that the ratio of intratumoral CD8 + T cells to T reg cells correlated with intratumoral IDO expression in patients. Although it is possible that altered function of antigen-presenting cells, which also express Ido, contributed to the T cell effects we observed in mouse GIST, Ido protein was detected mostly within the actual tumor cells.
A role for Etv4 or other ETS-family transcription factors in Ido1 transcriptional regulation has not been previously demonstrated. ETSfamily transcription factors are oncogenic in Ewing's sarcoma, prostate cancer and melanoma, and they have recently been shown to be a lineage-survival factor that cooperates with KIT in GIST tumorigenesis 42 . We found that imatinib rapidly reduced Etv4's expression, disrupting its binding to the Ido1 promoter. Additionally, imatinib did not decrease IDO protein levels in a resistant GIST cell line. This link between oncogenic KIT signaling and the immunosuppressive enzyme IDO suggests that acquired resistance to imatinib, which occurs most frequently owing to a secondary KIT mutation, may restore intratumoral IDO. Consistent with this hypothesis, we observed that the ratio of CD8 + T cells to T reg cells in human GISTs with acquired resistance to imatinib was significantly lower than in sensitive tumors, and resistance was associated with greater IDO1 expression than that seen in sensitive tumors. Tumor progression has been associated with IDO recovery in other cancers [43] [44] [45] . Thus, molecular and immune resistance in GIST appear to be intertwined.
Although targeted agents are effective, they are not curative, at least for solid tumors. We combined imatinib with CTLA-4 blockade, a well-established immunotherapeutic approach that acts synergistically with other systemic agents [46] [47] [48] [49] . Recently, CTLA-4 blockade has become the first treatment to prolong survival in patients with advanced melanoma 50 . The observation that CTLA-4 blockade acts synergistically with imatinib in mouse GIST demonstrates the potential of combining molecular and immune therapy in human GIST. Our data raise the possibility of treating human melanoma with a combination of CTLA-4 blockade and either imatinib for KIT-mutant tumors 51 or PLX4032 for V600E BRAF-mutant tumors 52, 53 .
In conclusion, our findings reveal a striking role of T cells in the antitumor effects of targeted therapy. Furthermore, oncogenic signaling in GIST is responsible for tumor-cell IDO expression, implying that acquired resistance to targeted therapy could result in the re-emergence of local immunosuppression. Combined molecular and immune therapy may improve outcomes in human GIST and other cancers treated with targeted agents.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
